Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Viatris Inc.. A complete text table follows the diagram.
A global medicines portfolio mixes high-volume legacy brands with specialty products, while Lipitor, Norvasc and Lyrica remain the largest named revenue anchors.
Swipe to explore
The filing reports $3.5097 billion consolidated net sales. The named-product group is the exact sum of disclosed key products; the remainder is an exact residual and is not an estimate of undisclosed products.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Viatris medicines | 1 | $3.5B | $3.510B quarterly net sales |
| Selected disclosed products | 2 | $1.5B | 43% of net sales |
| Other and undisclosed products | 2 | $2.0B | Exact residual |
| Lipitor | 3 | $462M | Largest named product |
| Norvasc | 3 | $210M | Cardiovascular brand |
| Lyrica | 3 | $121M | Pain and neurological brand |
| Eleven other named products | 3 | $703M | Exact sum of remaining disclosed products |
| From | To | Value |
|---|---|---|
| Viatris medicines | Selected disclosed products | $1.5B |
| Viatris medicines | Other and undisclosed products | $2.0B |
| Selected disclosed products | Lipitor | $462M |
| Selected disclosed products | Norvasc | $210M |
| Selected disclosed products | Lyrica | $121M |
| Selected disclosed products | Eleven other named products | $703M |